On June 28, 2021 Nimble Therapeutics and RayzeBio reported the companies have entered a strategic collaboration to discover and develop novel peptide-based radiopharmaceuticals for treatment of cancer (Press release, Nimble Therapeutics, JUN 28, 2021, View Source [SID1234584425]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to welcome RayzeBio to our growing family of partners," said Jigar Patel, Ph.D., CEO of Nimble Therapeutics. "Through our pioneering work, we have built a platform to rapidly identify drug-like hits and optimize them into leads, and conduct elaborate medicinal chemistry campaigns to engineer candidates with optimal potency, selectivity, stability, and other important attributes. This agreement with RayzeBio underscores the value inherent in Nimble’s platform to advancing the radiopharmaceutical field."

"Nimble’s platform technology is promising," said Ken Song, M.D., CEO of RayzeBio. "Nimble’s rational approach to using its platform to identify novel peptide-like molecules allows us to further expand our radiopharmaceutical pipeline and pursue multiple therapeutic programs in parallel."

Under the terms of the agreement, Nimble will receive an undisclosed upfront payment, research reimbursements and may also receive further milestone payments and royalties on sales of resulting products. RayzeBio has exclusive rights to develop and commercialize peptides discovered under the collaboration, and an option to further expand the collaboration to include additional targets.